Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229563 | 1.00 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL426117 | 0.88 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL1892821 | 0.85 | HTR6 (0.54) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL20841427 | 0.83 | HTR6 (0.63) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29829793 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL20762478 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL17597401 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL424532 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL29365890 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL706426 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| CN-111108105-B | Heterocyclic compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-111225915-B | Imidazopyridine compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-9126984-B2 | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS SA (BE) | 2015-09-08 | — | — | US | disclosed |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-13 | — | — | US | disclosed |
| WO-2015067782-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS SA (BE) | 2015-05-14 | — | — | US | disclosed |
| WO-2012117216-A1 | N- (ARYLALKYL) - 1H- INDOLE- 2 - SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-09-07 | — | — | WO | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| WO-2010109230-A1 | NOVEL PRODRUGS | PHARMINOX LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109230-A1 | NOVEL PRODRUGS | PHARMINOX LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 101/4885MEN1 4785/4885KMT2A 2859/4885 |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | HTR6 3579/4885MEN1 1694/4885KMT2A 2728/4885 |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | HTR6 4072/4885MEN1 8/4885KMT2A 246/4885 |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | HTR6 4105/4885MEN1 3281/4885KMT2A 1220/4885 |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | TUBB, TUBB3, TUBB1 | HTR6 592/4885MEN1 1042/4885KMT2A 3095/4885 |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 61/4885MEN1 4568/4885KMT2A 3391/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | HTR6 4105/4885MEN1 3281/4885KMT2A 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.